CC
SANA icon

Clearline Capital’s Sana Biotechnology SANA Stock Holding History

Clearline Capital’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-524,547
Closed -$1.86M – 130
2025
Q3 		$1.86M Buy
524,547
+114,012
+28% +$412K 0.09% 83
2025
Q2 		$1.12M Hold
410,535
– – 0.04% 93
2025
Q1 		$690K Buy
+410,535
New +$1.15M 0.04% 100

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Clearline Capital's SANA Position: Q4 2025 in Review

Clearline Capital sold out of Sana Biotechnology (SANA) in Q4 2025, closing a stake of 524,547 shares — an estimated $1.86M sold.

Clearline Capital first reported a position in SANA in Q1 2025 and held it in 3 quarters. The position peaked at $1.86M in Q3 2025. 203 funds tracked by Wall St. Rank hold SANA as of Q4 2025.

  • Clearline Capital reported no remaining Sana Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Clearline Capital sold 524,547 Sana Biotechnology shares in Q4 2025, an estimated $1.86M.
  • Clearline Capital first reported a position in Sana Biotechnology in Q1 2025 and held it in 3 quarters.
  • Clearline Capital's Sana Biotechnology position peaked at $1.86M in Q3 2025.
  • 203 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2025.

Based on Clearline Capital's 13F filing for Q4 2025, filed 17 Feb 2026.